Advertisement

EDITORIAL COMMENT

  • Colton Walker
    Affiliations
    Department of Urology, University of Michigan, Ann Arbor, MI
    Search for articles by this author
  • Udit Singhal
    Affiliations
    Department of Urology, University of Michigan, Ann Arbor, MI
    Search for articles by this author
  • Jeffrey J. Tosoian
    Correspondence
    Address correspondence to: Jeffrey J. Tosoian, M.D., M.P.H., Urologic Oncology, Department of Urology, The University of Michigan, 1500 E. Medical Center Drive, TC 3875 SPC 5330, Ann Arbor, MI 48109.
    Affiliations
    Department of Urology, University of Michigan, Ann Arbor, MI

    University of Michigan Rogel Cancer Center, Ann Arbor, MI

    Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI
    Search for articles by this author
      Multiparametric MRI (mpMRI) is increasingly used as part of the diagnostic evaluation for prostate cancer (PCa). While mpMRI with targeted biopsy appears to increase the detection of clinically-significant cancer and reduce overdiagnosis of low-risk cancer,
      • Ahmed HU
      • El-Shater Bosaily A
      • Brown LC
      • et al.
      Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS): a paired validating confirmatory study.
      a substantial proportion of Grade Group ≥2 (GG ≥2) lesions are not visible on mpMRI.
      • Salami SS
      • Kaplan JB
      • Nallandhighal S
      • et al.
      Biologic significance of magnetic resonance imaging invisibility in localized prostate cancer.
      ,
      • Johnson DC
      • Raman SS
      • Mirak SA
      • et al.
      Detection of individual prostate cancer foci via multiparametric magnetic resonance maging.
      The clinical significance of mpMRI-invisible lesions remains unclear, and limited data exist describing the course of mpMRI-negative PCa.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ahmed HU
        • El-Shater Bosaily A
        • Brown LC
        • et al.
        Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS): a paired validating confirmatory study.
        Lancet. 2017; 389: 815-822https://doi.org/10.1016/S0140-6736(16)32401-1
        • Salami SS
        • Kaplan JB
        • Nallandhighal S
        • et al.
        Biologic significance of magnetic resonance imaging invisibility in localized prostate cancer.
        JCO Precis Oncol. 2019; : 1-12https://doi.org/10.1200/po.19.00054
        • Johnson DC
        • Raman SS
        • Mirak SA
        • et al.
        Detection of individual prostate cancer foci via multiparametric magnetic resonance maging.
        Eur Urol. 2019; 75: 712-720https://doi.org/10.1016/j.eururo.2018.11.031
        • Vargas HA
        • Akin O
        • Shukla-Dave A
        • et al.
        Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.
        Radiology. 2012; 265: 478-487https://doi.org/10.1148/radiol.12120041
        • Le JD
        • Tan N
        • Shkolyar E
        • et al.
        Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: Correlation with whole-mount histopathology.
        Eur Urol. 2015; 67: 569-576https://doi.org/10.1016/j.eururo.2014.08.079
        • Truong M
        • Hollenberg G
        • Weinberg E
        • Messing EM
        • Miyamoto H
        • Frye TP
        Impact of gleason subtype on prostate cancer detection using multiparametric magnetic resonance imaging: correlation with final histopathology.
        J Urol. 2017; 198: 316-321https://doi.org/10.1016/j.juro.2017.01.077
        • Hurrell SL
        • McGarry SD
        • Kaczmarowski A
        • et al.
        Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging.
        J Med Imaging. 2017; 5: 1https://doi.org/10.1117/1.jmi.5.1.011004
        • Norris JM
        • Carmona Echeverria LM
        • Bott SRJ
        • et al.
        What Type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort.
        Eur Urol. 2020; 78: 163-170https://doi.org/10.1016/j.eururo.2020.04.029
        • Parry MA
        • Srivastava S
        • Ali A
        • et al.
        Genomic evaluation of multiparametric magnetic resonance imaging-visible and -nonvisible lesions in clinically localised prostate cancer.
        Eur Urol Oncol. 2019; 2: 1-11https://doi.org/10.1016/j.euo.2018.08.005
        • Sathianathen NJ
        • Omer A
        • Harriss E
        • et al.
        Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis negative predictive value of mu.
        Eur Urol. 2020; https://doi.org/10.1016/j.eururo.2020.03.048
        • Westphalen AC
        • McCulloch CE
        • Anaokar JM
        • et al.
        Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel.
        Radiology. 2020; 190646https://doi.org/10.1148/radiol.2020190646